The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive genomic profiling to identify tumor mutational burden (TMB) as an independent predictor of response to immunotherapy in diverse cancers.
 
Aaron Goodman
No Relationships to Disclose
 
Shumei Kato
No Relationships to Disclose
 
Lyudmila Bazhenova
Stock and Other Ownership Interests - Epic Sciences
Consulting or Advisory Role - Abbvie; ARIAD; AstraZeneca; Bristol-Myers Squibb; Genentech/Roche; Genoptix; Heat Biologics; Novartis; Pfizer; Trovagene
Speakers' Bureau - AstraZeneca; Genentech; Novartis; Pfizer
Research Funding - BeyondSpring Pharmaceuticals
 
Sandip Pravin Patel
No Relationships to Disclose
 
Garrett Michael Frampton
Employment - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Vincent A. Miller
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Phil Stephens
Employment - Foundation Medicine
Leadership - Foundation Medicine
Stock and Other Ownership Interests - Foundation Medicine
 
Razelle Kurzrock
Leadership - CureMatch
Stock and Other Ownership Interests - Actuate Therapeutics; CureMatch
Honoraria - AACR; AACR; Actuate Therapeutics; Casdin Capital; Casdin Capital; Casdin Capital; Casdin Capital; Cedars-Sinai; Frankel Group; Global Biomarkers Consortium; Health Advances; Janssen; Jubilant Biosys; Kaiser Permanente; Mayo Clinic Cancer Center; NCCN; Northwestern University; NXT Health Strategies; NXT Health Strategies; Pancreatic Cancer Action Network; Segal Cancer Center; Seminars in Oncology; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sequenom; Sylvester Cancer Center; Sylvester Cancer Center; The Dedham Group; UCSD Genomics Program Talk; XBiotech; XBiotech; Yale Cancer Center
Consulting or Advisory Role - AACR; Actuate Therapeutics; CTRC-EAB San Antonio; Janssen; Jubilant Biosys; Merck; SAIC NCI CCCT IDSE; Sequenom; XBiotech
Research Funding - Centocor Ortho Biotech; EMD Serono; EMD Serono; EMD Serono; Exelixis; Foundation Medicine; Genentech Mypath; GlaxoSmithKline; GlaxoSmithKline; Guardant Health; Merck; Merck; Merck Serono; Novartis; Pfizer; Roche/Genentech; Sequenom; XBiotech
Patents, Royalties, Other Intellectual Property - Patent; Patent; Patent; Patent
Travel, Accommodations, Expenses - AACR; AACR; ASCPT; Association of American Cancer Institutes; Caris Centers of Excellence; Caris Centers of Excellence; Cedars-Sinai; CureMatch; EMD Serono; EMD Serono & Quintiles; EMD Serono & Quintiles; FDA-OCRA; Gateway Research Advisory Committee; Gateway Research Advisory Committee; Genentech; Global Biomarkers Consortium; Global Source Ventures/Novena Therapeutics; Guardant Health; Guardant Health; ICRP; Journal of Precision Medicine; Kaiser Permanente; Lynx Group; Mayo Clinic Cancer Center; MedImmune/JK Associates Medical Communications Group; Meyer; Orbimed/Global Source Ventures; Pancreatic Cancer Action Network; Sylvester Cancer Center; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma; WIN Pharma